Matthew Laurie

Matthew Laurie, Senior Scientist at Bristol Myers Squibb, works in analytical development within the cell therapy division. He specializes in developing sequencing-based assays to characterize gene-edited therapies, with a focus on confirming on-target edits and detecting unintended genomic events such as translocations and vector integration. Matthew also contributes to analytical strategies for regulatory submissions and develops methods to assess the molecular purity of critical raw materials, integrating sequencing approaches with complementary techniques to ensure product quality and safety.